Loading clinical trials...
Loading clinical trials...
A Phase I, Open-label, Pharmacokinetic Study of TVB-2640 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Conditions
Interventions
TVB-2640 - 50 mg
Locations
3
United States
Thomas C. Marbury
Orlando, Florida, United States
Eric J. Lawitz, MD
San Antonio, Texas, United States
Geza Lakner
Kistarcsa, Hungary
Start Date
May 1, 2023
Primary Completion Date
December 18, 2023
Completion Date
December 18, 2023
Last Updated
December 26, 2023
NCT07439939
NCT05597488
NCT06680583
NCT07471542
NCT07469319
NCT07324616
Lead Sponsor
Sagimet Biosciences Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions